The company’s consolidated revenue from operation rose by 15.7 per cent to Rs 10,931 crore for the March quarter as compared to Rs 9,447 crore in the year-ago period.
“I am pleased with well-rounded growth demonstrated in FY23 by the company. Several of our businesses including Specialty, India and Emerging markets have continued to progress well. Our Specialty business remains on growth path and we are committed to continue scaling it up,” said Dilip Shanghvi, Managing Director of the company.
Formulation sales in the US for the full year FY23 were $1,684 million up 10.3 per cent over the same period last year. US formulation sales were $430 million for Q4FY23, a growth of 10.5 per cent over Q4 last year and accounted for about 33 per cent of total consolidated sales for the quarter, the company said in a BSE filing.
Taro’s full year FY23 sales were $573 million, up about 2.1 per cent over same period last year. Taro’s reported net profit for FY23 was $25.4 million compared to $58.3 million. Taro posted Q4FY23 sales of $ 147 million, up by 2.3 per cent YoY and net profit of about $6.9 million, lower by 74.7 per cent over adjusted net profit of Q4 last year.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.